Cannabis Report
Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

Add NVCN Price Alert      Hide Sticky   Hide Intro
Moderator: Lone Wolf, Joecanada13
Search This Board: 
Last Post: 9/19/2018 3:01:50 PM - Followers: 234 - Board type: Free - Posts Today: 0

Trading for
$0.061 as of Thurs. March 29th, 2018, well under two recent Price Targets of $2.00 and $0.50.
Increased chatter amongst investors of a Partnership or Buyout, see below. 

Latest Analyst Ratings:

March 29th, 2018 3:07 AM EDT
Neovasc Inc. PT updated to $2.00 at Leerink Partners, states that 'Tiara Clinical Trials Continue to Progress' Maintains 'Outperform' Rating.

March 29th, 2018 
Canaccord Genuity Updates Neovasc Inc (US) (NVCN) Price Target to $0.50 and has a "Buy" rating.

Latest Earnings Report - March 28th, 2018
EPS of $-0.28 misses by $-0.02 
Revenue of $5.39M (- 43.3% Y/Y) beats by $1.29M

Trader's takeaway from the latest Earnings Report: (Updated on April 1st, 2018)
1. No R/S mentioned, 2. Tiara Prescreen implementation in Europe soon (as early as this week), 3. Updates on Tiara / Reducer enrollments shown to have been very successful and increasing in size, 4. Cash to last through Q3 2018, 5. Revenues were down/but so were expenses.

Also on the conference call, they reported that the $112 M lawsuit has been fully paid and settled. Neovasc said that “there are no other monetary damages arising from the award,” and announced that it will remain the joint inventor of its ‘964 patent related to its Tiara transcatheter mitral valve replacement device. Neovasc will share the patent along with 2 employees of CardiAQ Valve, with both parties “having freedom to use the patent without an obligation to pay royalties to the other", according to a press release. Source: NeoVasc shares surge 45% on affirmed Tiara patent case decision against Edwards.

Possible Partnership in the works?
This was taken from the latest Earnings Conference call on March 28th, 2018 (link to entire transcript provided above, courtesy of
Newly acquired CEO/President Fred Colen hints at being open to a partnership.  Have a look at what he says:
Possible partnership?

Possible Buy Out in the works? 
Check out newly acquired CEO Fred Colen's bio below (spoiler alert: he worked with $BSX for 8 years as CTO) and see how this all ties together. 

Don't Be Surprised if Boston Scientific (BSX) Buys Neovasc (NVCN)- JMP  

MARCH 30, 2018 Article:

Neovasc has a unique opportunity to take a share of that US$16.2 Billion with this patent along with many other patents that they own.
Patent # 

Neovasc's Tiara and other TMVR devices
US$75 MILLION AGREEMENT 12/02/16}}}}

Neovasc and Boston Scientific Reach US$75 Million Agreement 
12/2/2016 7:00:00 AM - PR Newswire 

Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities 
12/2/2016 7:00:00 AM - PR Newswire 

NVCN + BSX = 15% stake = +350% for stock


Fred Colen - President and CEO

Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.  

"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member." 

Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years, including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry. 

Also note:
$BSX Boston Scientific laid off 300 employees just recently on March 27th, 2018
, perhaps to make room for the takeover of $NVCN ?? Who knows?? They already own 15% of NVCN.


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 




                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"


Concensus Recommendation courtesy of 
Updated: April 1st, 2018:   STRONG BUY.

STRONG BUY                                  
Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN News: Report of Foreign Issuer (6-k) 09/19/2018 04:38:27 PM
NVCN News: Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany 09/19/2018 10:20:00 AM
NVCN News: Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany 09/19/2018 10:20:00 AM
NVCN News: Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany 09/19/2018 10:20:00 AM
NVCN News: Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany 09/19/2018 10:20:00 AM
News News Alert: Report of Foreign Issuer (6-k) 09/19/2018 04:38:27 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#10378  Sticky Note They are in the process of being acquired. petergeorge 08/04/18 05:44:45 PM
#4414  Sticky Note Cliff note DD packet for those new to maz1978 03/10/18 10:12:07 AM
#10613   The funny thing about DCTH, was that they Wantcash 09/19/18 03:01:50 PM
#10612   No they got delisted. I was in DCTH. Wantcash 09/19/18 02:48:14 PM
#10611   Delcath Systems (DCTH) after RS up to the moon lister 09/19/18 02:15:01 PM
#10610   no logic behind lister 09/18/18 03:28:48 PM
#10609   EPIC FAIL Wantcash 09/18/18 02:57:18 PM
#10608   I'm staying in ... bad luck lister 09/18/18 12:33:13 PM
#10607   Well I sold out earlier this morning. Took Wantcash 09/17/18 05:18:21 PM
#10606   Sold today with a $5k loss. Might JFBroderick 09/17/18 05:00:35 PM
#10605   and no one knows why lister 09/17/18 04:34:30 PM
#10604   She goes down, down , down, down all Wantcash 09/17/18 03:43:49 PM
#10603   Don't forget they also have to maintain a Wantcash 09/17/18 12:03:28 PM
#10602   Just me, but I don't think this is Wantcash 09/17/18 10:54:13 AM
#10601   theory and praxis. praxis is the bad luck lister 09/16/18 02:19:50 PM
#10600   In theory yes... YW Don 09/16/18 01:25:43 PM
#10599   So this means the value of my portfolio lister 09/16/18 01:03:23 PM
#10598   The price after RS is defined by the Don 09/16/18 09:12:24 AM
#10597   is the share price already defined after RS ? lister 09/16/18 08:42:15 AM
#10596   I invested in three other companys, all with lister 09/15/18 12:25:02 PM
#10595   The company is the same and.....? JFBroderick 09/15/18 12:23:01 PM
#10594   yes but what is the share price after lister 09/15/18 12:17:54 PM
#10593   1 for 100 coming September 21st. Why JFBroderick 09/15/18 11:44:37 AM
#10592   nssrr5- On your foot. Crapola2theleft 09/13/18 05:43:38 PM
#10591   * * $NVCN Video Chart 09-13-18 * * ClayTrader 09/13/18 04:38:28 PM
#10590   If we knew where the bottom was we nsomniyak 09/13/18 04:13:08 PM
#10589   I am thinking of getting in but where nssrr5 09/13/18 02:21:01 PM
#10588   OUCH! Crapola2theleft 09/13/18 02:12:45 PM
#10587   Looks like no one wants to sell cheap Never_Post 09/13/18 10:08:07 AM
#10586   Two more days of Dilution per agreement. Never_Post 09/12/18 06:30:37 PM
#10585   i agree with you. Unless something happens before brizer211 09/12/18 04:08:55 PM
#10584   before and after the RS - the same lister 09/12/18 04:00:36 PM
#10583   ..."a leader in the development..." ups,leader without customers... lister 09/12/18 03:16:45 PM
#10582   VANCOUVER, Sept. 12, 2018 /CNW/ - Neovasc Inc. brizer211 09/12/18 02:33:01 PM
#10581   Hi Don, $1 before the RS and on lister 09/12/18 12:55:56 AM
#10580   Never seen a second extension. Didn’t know they Don 09/11/18 09:45:25 PM
#10579   I understand that this was an attempt at Wantcash 09/11/18 08:24:30 PM
#10578   Yeah, well they got the full 6 months Don 09/11/18 08:19:44 PM
#10577   IMO the reason why they didn't get a Wantcash 09/11/18 08:08:39 PM
#10576   Want- OOPS! Crapola2theleft 09/11/18 06:18:41 PM
#10575   Yes, clearly... Hazmat927d 09/11/18 04:01:52 PM
#10574   BTW - Warrants are reversed too. Never_Post 09/11/18 04:01:05 PM
#10573   Hard to make something positive out of this Never_Post 09/11/18 03:59:44 PM
#10572   WHAT IF... ANNOUNCING RS IN 1 MO FORCES ALL Hazmat927d 09/11/18 03:48:01 PM
#10571   Oops .typo Wantcash 09/11/18 03:22:34 PM
#10570   I'm not talking about the suit with EW, Wantcash 09/11/18 03:18:51 PM
#10569   The ruling is Thursday Sept 13. Wantcash 09/11/18 03:17:36 PM
#10568   NVCN just made the news at Zero Hedge. overachiever 09/11/18 03:02:37 PM
#10567   Want- Do you have any idea how long Crapola2theleft 09/11/18 02:36:42 PM
#10566   Never- I totally agree one thousand and one Crapola2theleft 09/11/18 02:33:34 PM
#10565   That’s not gonna create a 100% run. 20-30% MAYBE... Hazmat927d 09/11/18 02:31:06 PM
#10564   If the lawsuit judgment goes in our direction Wantcash 09/11/18 02:08:59 PM